| Business Summary | | Vysis,
Inc.
is
a
genomic
disease
management
company
that
develops,
commercializes
and
markets
Deoxyribonucleic
Acid
(DNA)-based
clinical
products
that
provide
information
critical
to
the
evaluation
and
management
of
cancer,
prenatal
disorders
and
other
genetic
diseases.
Vysis
markets
six
United
States
Food
and
Drug
Administration-
or
foreign-cleared
or
approved
clinical
products
in
addition
to
distributing
over
300
analyte
specific
reagent
and
research
products
through
its
direct
sales
operations
in
the
United
States
and
Europe
and
a
worldwide
distribution
network
covering
59
countries.
The
Company's
wholly
owned
subsidiary,
Gene-Trak
Systems
Industrial
Diagnostics
Corporation,
manufactures
and
markets
food
testing
kits
based
on
DNA
probes.
The
Company
operates
in
two
business
segments,
genetic
testing
and
food
testing
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vysis
is
a
genomic
disease
management
company
that
develops
and
markets
clinical
products
that
provide
critical
information
for
the
evaluation
and
management
of
cancer,
prenatal
disorders
and
other
genetic
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
27%
to
$13.3
million.
Net
income
from
continuing
operations
totalled
$2.1
million,
vs.
a
loss
of
$2.2
million.
Results
reflect
higher
clinical
and
ASR/Research
product
sales,
and
the
absence
of
$1.5
million
in
clinical
data
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Walter Quanstrom, Ph.D., 58 Chairman | -- | John Bishop, 56 Pres,
CEO | $268K | John Sluis, 55 CFO,
Sr. VP-Fin. | -- | Paul Steuperaert, 61 Pres-
European Operations | 169K | William Murray, 47 VP,
Sec., Gen. Counsel | 158K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|